Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?

Robyn L Woods, Andrew M Tonkin, Mark R Nelson, Helena C Britt and Christopher M Reid
Med J Aust 2009; 190 (11): . || doi: 10.5694/j.1326-5377.2009.tb02587.x
Published online: 1 June 2009

Robust evidence remains to be gathered

Whenever possible, clinical decision making should be evidence-based. In reality, the evidence may be incomplete and the practitioner must use personal clinical judgement. This should be based on recommendations or guidelines provided by authoritative groups.

  • Robyn L Woods1
  • Andrew M Tonkin1
  • Mark R Nelson2
  • Helena C Britt3
  • Christopher M Reid1

  • 1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.
  • 2 Menzies Research Institute, University of Tasmania, Hobart, TAS.
  • 3 Australian General Practice Statistics and Classification Centre, School of Public Health, University of Sydney, Sydney, NSW.

Competing interests:

Andrew Tonkin, Mark Nelson and Christopher Reid have received support from Bayer HealthCare (a manufacturer of aspirin) for their ongoing NHMRC-supported ASPREE trial. Bayer HealthCare provided an educational grant (US$250 000) and is now supplying aspirin and placebo for ASPREE.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.